Rank 50 • Biotech & Discovery
Absci
Applies generative AI and high-throughput screening to design and validate novel therapeutic antibodies.
Visit website- Signal Score
- 87
- Total raised
- $230M
- Stage
- Public
- Founded
- 2011
- Headquarters
- Vancouver, USA
- Region
- North America
Their signal
Absci accelerates the timeline of biologic creation using zero-shot generative AI. Its high-profile partnerships with AstraZeneca and Almirall demonstrate the market demand for its scalable antibody design technology.
Signal Score 87editorial estimate, see how it is built
Total raised, quality of investors and recency of the last round.
Revenue trajectory, customer count, hiring and market pull.
Peer-reviewed evidence, FDA/CE clearances and live health-system deployments.
Founder track record, clinical depth on the bench and technical leadership.
Search presence, press coverage, founder and brand reach, and how often the company shows up where buyers look.
Also in Biotech & Discovery
Did we miss something?
Change, add or remove details on this company. Our desk reviews every request.
Figures are subjective research desk estimates compiled from public sources and refreshed monthly, published as editorial commentary. Company marks are shown for identification only and imply no endorsement or affiliation. Want a correction, an update or removal? and see our corrections and removals policy.